AgMedica Bioscience

About

Organization overview

AgMedica Bioscience Inc. is an authorized licensed cultivator, processor and seller under the Cannabis Act Health Canada granted AgMedica Bioscience Inc. (formerly AgriMed Botanicals Inc.) its first license from Health Canada on On Dec 8th 2017. About AgMedica AgMedica is a licensed producer under the Cannabis Act and Regulations and is focused on the cultivation of quality, consistent medical cannabis. The company’s Riverview cultivation facility is located in Chatham, Ontario. The Phase I facility has annual capacity of 6,000 kg of indoor cannabis. Plans are in place to expand this capacity within the existing building to 26,500kg. The company’s second indoor facility is in the detailed review stage at Health Canada to become the Cannabis Act and Regulations licensed producer and is forecast to add an additional 40,000 kg in annual capacity once fully built, providing AgMedica with a total projected indoor production capacity of 66,500 kg per year. AgMedica’s vision is to be a global leader in the production of cannabis and cannabis-derived products that improve the health and well-being of its patients. The company is working to understand and serve the needs of its patients, partners, ensuring that its products, their quality and the ongoing commitment that the Company brings to health and well-being remain its fundamental priorities. The AgMedica team is dedicated to the development of cannabis derived products for medical, adult-use recreational and ultimately pharmaceutical purposes. This will be accompanied through plant and product research and development, innovative production practices, comprehensive clinical and health benefit assessments and a commitment to patient value. AgMedica is committed to developing and commercializing innovative products, processes and services. Name Change to AgMedica AgMedica Bioscience Inc. (formerly AgriMed Botanicals Inc. or AMBI) changed its name on December 6, 2017. “Our name change to AgMedica Bioscience reflects our evolution and strategic vision to become a dominant vertically integrated player in the medical cannabis market and to invest in world-class research and development to develop and commercialize clinically-proven cannabis-derived pharmaceutical products for human and veterinary use.” said CEO, Art Vander Pol.